Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D0C8DD
|
|||
| Former ID |
DCL000554
|
|||
| Drug Name |
Losmapimod
|
|||
| Synonyms |
585543-15-3; GSK-AHAB; GW856553; GW856553X; UNII-F2DQF16BXE; F2DQF16BXE; GW-856553; 6-[5-(cyclopropylcarbamoyl)-3-fluoro-2-methylphenyl]-N-(2,2-dimethylpropyl)pyridine-3-carboxamide; Losmapimod [USAN:INN]; Losmapimod (GW856553X); GSKAHAB; GW 856553X; SB 856553; Losmapimod (USAN/INN); SCHEMBL1070401; GTPL7835; CHEMBL1088752; EX-A486; CHEBI:131167; KKYABQBFGDZVNQ-UHFFFAOYSA-N; MolPort-009-194-138; losmapimod pound> HMS3653G19; BCP09909; AOB87105; ZINC35793138; s7215; BDBM50418610; 2523AH; AKOS015994587
Click to Show/Hide
|
|||
| Drug Type |
Small molecular drug
|
|||
| Indication | Acute coronary syndrome [ICD-11: BA41; ICD-9: 411.1] | Phase 3 | [1], [2] | |
| Company |
GSK
|
|||
| Structure |
 |
Download2D MOL |
||
| Formula |
C22H26FN3O2
|
|||
| Canonical SMILES |
CC1=C(C=C(C=C1F)C(=O)NC2CC2)C3=NC=C(C=C3)C(=O)NCC(C)(C)C
|
|||
| InChI |
1S/C22H26FN3O2/c1-13-17(9-15(10-18(13)23)21(28)26-16-6-7-16)19-8-5-14(11-24-19)20(27)25-12-22(2,3)4/h5,8-11,16H,6-7,12H2,1-4H3,(H,25,27)(H,26,28)
|
|||
| InChIKey |
KKYABQBFGDZVNQ-UHFFFAOYSA-N
|
|||
| CAS Number |
CAS 585543-15-3
|
|||
| PubChem Compound ID | ||||
| PubChem Substance ID |
16654942, 23674056, 42694602, 78485146, 102979941, 103744992, 124490379, 125434298, 134339121, 135262190, 137052680, 139361704, 152134006, 162222430, 163367634, 163893996, 180415893, 184696695, 187072015, 196409639, 198938694, 210274682, 210280315, 223366166, 223674972, 224108956, 227317473, 249097192, 251963106, 251971296, 252451562, 252472344
|
|||
| ChEBI ID |
CHEBI:131167
|
|||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 7835). | |||
| REF 2 | Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800023191) | |||
| REF 3 | Clinical pipeline report, company report or official report of GlaxoSmithKline (2009). | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.